Abstract
CD28 is the major costimulatory receptor on T cells regulating proliferation, survival and effector function. Acquired mutations in the extracellular domain of CD28 have been identified in patients with cutaneous T cell lymphoma, angioimmunoblastic T cell lymphoma and other T cell neoplasms, suggesting it may contribute to disease pathogenesis. We used a heterologous system in which mutant human CD28 was expressed on primary murine T cells deficient in CD28 to ascertain how specific mutations identified in a genetic screen of patients with cutaneous T cell lymphoma affected normal T cell function. All three mutant CD28 proteins examined enhanced CD28-dependent T cell proliferation and effector function. These data suggest that the mutant CD28 isoforms could accelerate tumor cell growth and increase tumor burden in affected patients. Interruption of CD28:ligand interactions may be an effective, targeted therapy for a subset of patients whose tumors bear the mutant CD28 receptor.
| Original language | English |
|---|---|
| Pages (from-to) | 28-34 |
| Number of pages | 7 |
| Journal | Cellular Immunology |
| Volume | 319 |
| DOIs | |
| State | Published - Sep 2017 |
Keywords
- CD28
- Costimulation
- Cutaneous T cell lymphoma
Fingerprint
Dive into the research topics of 'Functional analysis of acquired CD28 mutations identified in cutaneous T cell lymphoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver